

CASE REPORT



OPEN ACCESS

Received: 19.10.2022

Accepted: 23.11.2022

Published: 13.12.2022

Citation: Sunil P, Swathi H, Kauser M, Marulasreshta GD, Kumar SRV, Prashanth G. (2022). Mixed Connective Tissue Disorder: A Rare Case Report. International Journal of Preclinical & Clinical Research. 3(3): 74-77. <https://doi.org/10.51131/IJPCCR/v3i3.22.40>

* **Corresponding author.**

murtuza4@gmail.com

Funding: None

Competing Interests: None

Copyright: © 2022 Sunil et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Published By Basaveshwara Medical College & Hospital, Chitradurga, Karnataka

ISSN

Print: XXXX-XXXX

Electronic: 2583-0104

Mixed Connective Tissue Disorder: A Rare Case Report

Pattanshetty Sunil¹, Hadagali Swathi², Murtuza Kauser^{3*}, G D Marulasreshta², S R Vagesh Kumar⁴, G Prashanth⁵

1 Postgraduate, Department of General Medicine, Basaveshwara Medical College and Hospital, Chitradurga, Karnataka, India

2 Senior resident, Department of General Medicine, Basaveshwara Medical College and Hospital, Chitradurga, Karnataka, India

3 Professor, Department of General Medicine, Basaveshwara Medical College and Hospital, Chitradurga, Karnataka, India

4 Professor and Head Of Department, Department of General Medicine, Basaveshwara Medical College And Hospital, Chitradurga, Karnataka, India

5 Professor and Dean, Department of General Medicine,, Basaveshwara Medical College and Hospital, Chitradurga, Karnataka, India

Abstract

MCTD is a rare disease with overlapping features of many connective tissue disorder and the presence of positive anti-U1RNP antibodies with anti-ssA (Ro), anti-ssB (La) being negative. We report a case with fever and edema of upper limb and lower limb small joints associated with violaceous discolouration which on further evaluation led to diagnosis of MCTD. A female aged 44 years presented with history of fever of moderate degree with no diurnal variation and subsides on taking medication for 7 days and had also noticed ecchymoses followed by maculopapular rashes (violaceous) associated with tenderness of fingers and toes (more on exposure to cold). On further evaluation led to a diagnosis of MCTD. This case report urges the clinicians to exercise great caution for connective tissue diseases in patient presenting with similar history. This rare case of disease is uncommon in the available literature, especially for this ethnicity or region. This report should be of great interests to all diagnosticians of internal medicine.

Keywords: Mixed connective tissue disorder; Raynaud's phenomenon; sclerodactyly; Anti-U1nRNP antibody; Scleroderma

Introduction

MCTD is an autoimmune disease which was first described in 1972 by Sharp et al. as a disease syndrome with overlapping features of systemic sclerosis, systemic lupus erythematosus (SLE) and

polymyositis.⁽¹⁾ Therefore, MCTD is sometimes referred to as an overlap disease. The initial presentation of the patients usually comprises nonspecific signs such as swollen digits, arthralgia, myalgia or muscle weakness, acid reflux or dysphagia, Raynaud's phenomenon,

shortness of breath on activity, a general malaise and fatigue. Over a period the symptoms are dominated by symptoms of either of one of the three illness along with high titers of anti-U1RNP antibody. The etiology of the mixed connective tissue disorder is unknown but being an autoimmune disease MCTD can run within families and is known to affect women more than men, with female to male ratio of 16:1.⁽²⁾ No causal association and the varied presentation, makes the diagnosis of this rare condition difficult.

We encountered one such case with fever, edema of upper limb and lower limb small joints with violaceous discoloration and tenderness as the initial presentation that eventually led to the diagnosis of MCTD with no complications.

Case report

A 44-year-old female, a known hypothyroid and depression on regular treatment for 2 and 9 years respectively was admitted with complaints of fever (intermittent) with no diurnal variation and not associated with chills and rigor with violaceous discoloration and tenderness of small joints of upper limb and lower limb for 7 days. The tenderness was increasing every day in intensity and aggravated on exposure to cold/low temperatures. The fever responded to antipyretics.

On inquiring, she gave history of dyspeptic symptoms since two months with no history of dysphagia or difficulty in opening mouth, but on visualization microstomia was noted.

On examination, mild pallor present and temperature recorded 99.8F. She had edema of upper limb and lower limb small joints with violaceous discoloration and multiple ecchymoses and maculopapular rashes over forearm and lower limb. On palpation tenderness was present as explained above restricting her day-to-day activities and difficulty in getting up from sitting position or holding on to any object due to pain and swelling. Facial skin was taut with pinched up nose.

Physical examination Per Abdomen was normal. Cardio-vascular examination was within normal limits. Respiratory system and Nervous system examination provided no abnormal findings.

She was on, Tab. Thyroxine 25mcg 1-0-0, Tab. Oxcarbazepine 150mg 1-0-1, Tab. Chlordiazepoxide + Amitriptyline [25mg/10mg] 0-0-1, Tab. Clonazepam 1mg $\frac{1}{2}$ -0-1, Tab. Respirodone + Tri-hexiphenidyl [2mg/2mg] $\frac{1}{2}$ -0-1

The above mentioned drugs doesn't cause any vasculitis.

On investigating laboratory values are as follows

Hb- 9.4gm%, Total count- 12190cells/cumm, Platelet count- 1.06lakh cells/cumm

Peripheral smear- Normocytic Normochromic Anaemia with Leucocytosis and Thrombocytopenia, renal function was normal

Others

HIV 1&2- negative, HbsAg-negative, Anti HCV- negative, Dengue serology-negative, Weil-felix test-negative, Mp card test-negative, Serum calcium- 6.5

Pt/INR: P.time-14.3sec; Control-11.9sec; INR-1.2sec; APTT-24.5sec; APTTcontrol-35sec; Tsh-14.5 mcIU/ml; Urine(routine and microscopy)- within normal limits

Sonography (abdomen and pelvis)-grade 1 fatty changes; -no other significant abnormality detected.

Oesophago gastro duodenoscopy- Features consistent with chronic gastritis.

Psychiatry opinion was taken i/v/o of depression and was opined as Severe depressive episode with psychotic feature and was advised the following, Tab. Sertaraline 25mg 1-0-0; Tab. Zolpidem 5mg 0-0-1; Tab. Clonazepam 0.25mg sos

Dermatology opinion was taken i/v/o skin biopsy, opined as no significant thickening of skin noted[sclerodactyly] or active lesions of disease present at the time of examination for obtaining skin biopsy

X-ray of chest (Posterior-anterior view): within normal limits

2D-echo cardiogram: within normal limits

Our patient followed the Alarcon-Segovia diagnostic criteria (Table 1) with positive serology and three of five clinical criteria namely Raynaud's phenomenon, edema of hand, synovitis, myositis. Our patient also followed the Kasukawa diagnostic criteria (Table 2) with both the common symptoms of Raynaud's and swollen hands being present associated with positive serology and mixed findings of thrombocytopenia, muscle weakness.

Serological examination showed antibody to U1-nRNP/Sm positive. However other antinuclear antibody was negative (Table 3).

Diagnosis of MCTD was made

The management of the patient included, antibiotics, antipyretics, and medications for hypothyroidism were continued. Later the following were added to the management:

Tab. Shelcal 500mg 1-0-1; Inj. Dexamethasone 4mg I.V. 1-1-1 x 6days; Tab. Prednisolone 40mg 1-0-0; Tab. Nifedipine 10mg 1-0-0

The patient was discharged after 9days of hospitalization and is currently on tapering doses of steroids (every five days to 30mg, 20mg, 10mg, 5mg) with continuation of Thyroxine and medications as advised by psychiatrist.

Table 1. Alarcon-Segovia diagnostic criteria for mixed connective tissue disease

Serologic Criteria	Positive anti-U1RNP at hemagglutination titer >1:1600
Clinical Criteria	Edema of hands Synovitis Myositis Raynaud's Acrosclerosis

Table 2. Kasukawa diagnostic criteria for mixed connective tissue disease

1) Common Symptoms
Raynaud's Phenomenon
Swollen fingers or hands
2) Presence of Anti U1-nRNP
3) Mixed findings
A. Systemic lupus erythematosus (SLE) like Polyarthritis
Pericarditis/pleuritis Lymphadenopathy Facial erythema
Leucopenia/thrombocytopenia
B. Scleroderma like Sclerodactyly Pulmonary fibrosis
Esophageal dysmotility
C. Polymyositis like Muscle weakness High creatine phosphokinase (CPK) Myopathic electromyogram (EMG)
Requirement for diagnosis: At least one common symptom, with positive U1RNP antibodies and one or more findings in at least two of the three categories A, B, and C.

Table 3. Immunopathology Autoantibody/ENA profile(IgG)

Test name	Test result
Jo-1 antibody	negative
Antibody to Scl-70	negative
Antibody to sm(smith)	negative
Antibody to ss-A(Ro)	negative
Antibody to ss-B(La)	negative
Antibody to Rib.Po	negative
Antibody to U1-nRNP	Positive +++
Antibody to CENP B	negative
Antibody to dsDNA	negative
Antibody to Histones	negative
Antibody to Nucleosomes	negative
Antibody to PM-Sd	negative
Antibody to RO-52	negative
Antibodies to PCNA(proliferative cell nuclear antigen)	negative
Anti mitochondrial antibody-M2	negative
DFS70	Positive ++

**Fig 1.** depicting edema of upper limb and lower limb small joints with violaceous discoloration

Discussion

The initial history of Raynaud's phenomenon generalized swelling. Physical examination findings microstomia guided our laboratory and radiologic workup and thereafter helped us to reach the diagnosis.

MCTD is a rare disease with unknown etiology, but few cases have been reported after occupation of vinyl chloride,⁽³⁾ and even after breast augmentation surgeries.⁽⁴⁾ There are familial cases of MCTD with increased instance of HLADR4 compared with controls.

A 2011 Norwegian study showed a 3.8 per 100,000 prevalence of MCTD among adults, with an incidence of 2.1 per million per year.⁽⁵⁾ Mean age of onset was 31.9 years and more than three quarters of patients were females.⁽⁶⁾ This confirms the rarity of the disease and a predilection for female sex.

MCTD should be kept as a differential diagnosis when overlapping signs of autoimmune diseases are present such as swollen digits, arthralgia, myalgia or muscle weakness, acid reflux or dysphagia, Raynaud's phenomenon, shortness of breath on activity, a general malaise and fatigue. Many criteria have been described to classify MCTD. Table 1 gives the Alarcon-Segovia's criteria and Table 2 gives the

Kasukawa diagnostic criteria for mixed connective tissue disease. Alarcon-Segovia's criteria are simple and comprises five clinical manifestations in addition to the serological status.⁽⁷⁾

Our patient also followed the Kasukawa diagnostic criteria with both the common symptoms of Raynaud's and swollen hands being present associated with positive serology and mixed findings of thrombocytopenia.

Myositis clinically presenting as muscle weakness is more common than laboratory increase in muscle enzymes.

Lung function tests, especially the single breath diffusing capacity may be abnormal in many patients but only a small fraction of those are symptomatic. Pulmonary artery hypertension is not common in early MCTD.⁽⁸⁾ Pulmonary hypertension, occurring secondary to interstitial lung disease is an increasingly recognized complication.

Membranous glomerulopathy and mesangial proliferative glomerulonephritis are the main renal manifestations. Less common renal manifestations include diffuse proliferative glomerulonephritis, vascular or glomerular sclerosis. It is clinically manifested mainly with proteinuria, rarely with hematuria.⁽⁹⁾ Our patient urine examination was within normal limits.

The therapy for MCTD would combine a cocktail of drugs to suppress inflammation including NSAIDs like naproxen, COX-2 inhibitors like celecoxib, steroids such as prednisone, antimalarials (hydroxychloroquine) and immunosuppressants like azathioprine. Nifedipine, nitroglycerin, losartan is used for Raynaud's phenomenon. TNF blockers etanercept and TNF antibodies infliximab, adalimumab is used in inflammatory arthritis in some cases. So, two people with the same disease but different presentations would require an altogether different management.⁽¹⁰⁾

The use of therapeutic antibodies like rituximab, a CD20 receptor blocker in MCTD have shown benefit in cases of refractory polymyositis and lower CPK.⁽¹¹⁾

Conclusion

Systemic rheumatologic disease can hide behind rather non-specific and unrelated symptoms and signs. We therefore recommend holding a high degree of suspicion in the susceptible individuals, and always consider the possibility of presence of any autoimmune pathology where needed, because these diseases, as evident from the discussion before, can present with uncommon features and mimic some other trivial conditions initially. But it is always necessary to

diagnose early in order to decrease morbidity, and disease related complications. Patient once diagnosed needs to be monitored on regular basis as pulmonary hypertension presents late in the illness when other clinical signs are easily recognizable and should be treated aggressively as most deaths in mixed connective tissue disorders are due to heart failure caused by pulmonary arterial hypertension

References

- 1) Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). *The American Journal of Medicine*. 1972;52(2):148–159. Available from: [https://doi.org/10.1016/0002-9343\(72\)90064-2](https://doi.org/10.1016/0002-9343(72)90064-2).
- 2) Nakae K, Furusawa F, Kasukawa R. A nationwide epidemiological survey on diffuse collagen diseases: Estimation of prevalence rate in Japan. In: Kasukawa R, Sharp G, editors. *Mixed Connective Tissue Disease and Anti-nuclear Antibodies*. 1987;p. 9.
- 3) Kahn MF, Bourgeois P, Aeschlimann A, De Truchis P. Mixed connective tissue disease after exposure to polyvinyl chloride. *J Rheumatol*. 1989;16(4):533–538. Available from: <https://pubmed.ncbi.nlm.nih.gov/2746593/>.
- 4) Qkumagai Y, Shiokawa Y, Medsger TA, Rodnan GP. Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. *Arthritis Rheum*. 1984;27(1):1–12. Available from: <https://doi.org/10.1002/art.1780270101>.
- 5) Gunnarsson R, Molberg Ø, Gilboe IMM, Gran JT. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. *Annals of the Rheumatic Diseases*. 2011;70(6):1047–1051. Available from: <https://doi.org/10.1136/ard.2010.143792>.
- 6) Hench PK, Edington TS, Tam EM. The Evolving clinical spectrum of mixed connective tissue disease. *Arthritis Rheum*. 1975;18:404–412.
- 7) Alarcon-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. *J Rheumatol*. 1989;16(3):328–332. Available from: <https://pubmed.ncbi.nlm.nih.gov/2724251/>.
- 8) Haroon N, Nisha RS, Chandran V, Bharadwaj A. Pulmonary hypertension not a major feature of early mixed connective tissue disease: A prospective clinicoserological study. *J Postgrad Med*. 2005;51(2):104–111. Available from: <https://pubmed.ncbi.nlm.nih.gov/16006700/>.
- 9) Maldonado ME, Perez M, Pignac-Kobinger J. Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population. *J Rheumatol*. 2008;35(3):429–437. Available from: <https://pubmed.ncbi.nlm.nih.gov/18260175/>.
- 10) Ortega-Hernandez ODD, Shoenfeld Y. Mixed connective tissue disease: An overview of clinical manifestations, diagnosis and treatment. *Best Practice & Research Clinical Rheumatology*. 2012;26(1):61–72. Available from: <https://doi.org/10.1016/j.berh.2012.01.009>.
- 11) Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: An open-label prospective study. *J Rheumatol*. 2007;34(9):1864–1872. Available from: <https://pubmed.ncbi.nlm.nih.gov/17722224/>.